JP2021513857A5 - - Google Patents

Info

Publication number
JP2021513857A5
JP2021513857A5 JP2020543928A JP2020543928A JP2021513857A5 JP 2021513857 A5 JP2021513857 A5 JP 2021513857A5 JP 2020543928 A JP2020543928 A JP 2020543928A JP 2020543928 A JP2020543928 A JP 2020543928A JP 2021513857 A5 JP2021513857 A5 JP 2021513857A5
Authority
JP
Japan
Prior art keywords
seq
cells
domain
acid sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020543928A
Other languages
English (en)
Japanese (ja)
Other versions
JP7358369B2 (ja
JP2021513857A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/019065 external-priority patent/WO2019165156A1/en
Publication of JP2021513857A publication Critical patent/JP2021513857A/ja
Publication of JP2021513857A5 publication Critical patent/JP2021513857A5/ja
Application granted granted Critical
Publication of JP7358369B2 publication Critical patent/JP7358369B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020543928A 2018-02-23 2019-02-22 Cd83結合キメラ抗原受容体 Active JP7358369B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862634435P 2018-02-23 2018-02-23
US62/634,435 2018-02-23
US201862677783P 2018-05-30 2018-05-30
US62/677,783 2018-05-30
PCT/US2019/019065 WO2019165156A1 (en) 2018-02-23 2019-02-22 Cd83-binding chimeric antigen receptors

Publications (3)

Publication Number Publication Date
JP2021513857A JP2021513857A (ja) 2021-06-03
JP2021513857A5 true JP2021513857A5 (enExample) 2022-02-28
JP7358369B2 JP7358369B2 (ja) 2023-10-10

Family

ID=67686942

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020543928A Active JP7358369B2 (ja) 2018-02-23 2019-02-22 Cd83結合キメラ抗原受容体

Country Status (14)

Country Link
US (1) US12492254B2 (enExample)
EP (1) EP3755722A4 (enExample)
JP (1) JP7358369B2 (enExample)
KR (1) KR20200130324A (enExample)
CN (1) CN112004832A (enExample)
AU (1) AU2019226101A1 (enExample)
BR (1) BR112020017015A2 (enExample)
IL (1) IL276836A (enExample)
MA (1) MA51917A (enExample)
MX (1) MX2020008803A (enExample)
PH (1) PH12020500632A1 (enExample)
SG (1) SG11202007755YA (enExample)
WO (1) WO2019165156A1 (enExample)
ZA (1) ZA202005837B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019165156A1 (en) 2018-02-23 2019-08-29 H. Lee Moffitt Cancer Center And Research Institute Inc. Cd83-binding chimeric antigen receptors
AU2020333659A1 (en) * 2019-08-16 2022-02-24 H. Lee Moffitt Cancer Center And Research Institute Inc. Anti-CD83 chimeric antigen receptor expressing t regulatory cells
AU2020334893A1 (en) * 2019-08-16 2022-02-24 H. Lee Moffitt Cancer Center And Research Institute Inc. Chimeric antigen receptors for treating myeloid malignancies
EP4041404A4 (en) * 2019-09-30 2023-10-25 The Trustees of the University of Pennsylvania HUMANIZED ANTI-ALPHA RECEPTOR 4 ANTIBODY (GRF-ALPHA-4) AND CHIMERIC ANTIGEN RECEPTOR (CAR)
US20230051885A1 (en) * 2019-12-18 2023-02-16 H. Lee Moffitt Cancer Center And Research Institute Inc. Systems and Methods for Producing Efficacious Regulatory T Cells
US20230390391A1 (en) * 2020-01-22 2023-12-07 Regents Of The University Of Minnesota Bi-specific chimeric antigen receptor t cells targeting cd83 and interleukin 6 receptor
US20230107770A1 (en) * 2020-02-20 2023-04-06 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of enhancing immunotherapy using er stress pathway inhibitors
US20230321239A1 (en) * 2020-08-14 2023-10-12 H. Lee Moffitt Cancer Center And Research Institute Inc. Chimeric antigen receptor t cells for treating autoimmunity
WO2022183160A1 (en) * 2021-02-25 2022-09-01 H. Lee Moffitt Cancer Center And Research Institute Inc. Methods for treating cd83-expressing cancer
CN119331093B (zh) * 2024-11-04 2025-07-11 武汉伊莱瑞特生物科技股份有限公司 一种抗CD30的兔源Fab抗体及其制备方法和应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040185040A1 (en) 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
EP1572976B1 (en) 2002-11-21 2010-09-15 Celltech R & D, Inc. Modulating immune responses
GB0624500D0 (en) 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
US9228172B2 (en) 2008-06-19 2016-01-05 The Trustees Of The University Of Pennsylvania Inducible regulatory T-cell generation for hematopoietic transplants
CA2823782C (en) 2011-01-10 2019-05-07 Samuel Strober Enhancement of allogeneic hematopoietic stem cell transplantation
JP2013150592A (ja) 2011-07-01 2013-08-08 Genentech Inc 自己免疫疾患を治療するための抗cd83アゴニスト抗体の使用
JP2013040160A (ja) * 2011-07-01 2013-02-28 Genentech Inc 自己免疫疾患を治療するための抗cd83アゴニスト抗体の使用
WO2014117220A1 (en) * 2013-02-01 2014-08-07 Transbio Ltd Anti-cd83 antibodies and use thereof
US9422549B2 (en) 2013-02-26 2016-08-23 Axiomx, Inc. Methods for the production of libraries for directed evolution
AU2014318247B2 (en) 2013-09-13 2018-05-24 Michael Abrams Novel peptides and analogs for use in the treatment of oral mucositis
EP3209695A4 (en) 2014-10-23 2018-05-30 DendroCyte BioTech Pty Ltd Cd83 binding proteins and uses thereof
CA2964958A1 (en) * 2014-10-31 2016-05-06 The Trustees Of The University Of Pennsylvania Methods and compositions for modified t cells
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
WO2016126608A1 (en) * 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
JP6961490B2 (ja) 2015-04-08 2021-11-05 ノバルティス アーゲー Cd20療法、cd22療法、およびcd19キメラ抗原受容体(car)発現細胞との併用療法
AU2016274989A1 (en) 2015-06-12 2017-11-02 Immunomedics, Inc. Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
US11655452B2 (en) 2015-06-25 2023-05-23 Icell Gene Therapeutics Inc. Chimeric antigen receptors (CARs), compositions and methods of use thereof
KR20180118175A (ko) 2016-03-04 2018-10-30 노파르티스 아게 다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도
JP2019535262A (ja) 2016-11-11 2019-12-12 オートラス リミテッド キメラ抗原受容体
KR20200066613A (ko) 2017-09-13 2020-06-10 키라 바이오테크 피티와이 리미티드 치료 방법
KR20260026092A (ko) 2017-09-19 2026-02-25 메사추세츠 인스티튜트 오브 테크놀로지 키메라 항원 수용체 t 세포 요법을 위한 조성물 및 그의 용도
CN111787938A (zh) 2017-11-15 2020-10-16 诺华股份有限公司 靶向bcma的嵌合抗原受体、靶向cd19的嵌合抗原受体及组合疗法
WO2019136335A1 (en) 2018-01-05 2019-07-11 Gencyte Therapeutics, Inc. Precision molecular adaptor system for car-t immunotherapy
EP3749334B1 (en) 2018-02-08 2024-12-11 The Board of Trustees of the Leland Stanford Junior University Allogenic hematopoietic stem cell transplantation
WO2019165156A1 (en) 2018-02-23 2019-08-29 H. Lee Moffitt Cancer Center And Research Institute Inc. Cd83-binding chimeric antigen receptors
US20200108098A1 (en) 2018-02-23 2020-04-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. Anti-cd83 chimeric antigen receptor expressing t regulatory cells
US20200268797A1 (en) 2018-11-30 2020-08-27 Janssen Biotech, Inc. Gamma delta t cells and uses thereof
AU2020333659A1 (en) 2019-08-16 2022-02-24 H. Lee Moffitt Cancer Center And Research Institute Inc. Anti-CD83 chimeric antigen receptor expressing t regulatory cells
US20230051885A1 (en) 2019-12-18 2023-02-16 H. Lee Moffitt Cancer Center And Research Institute Inc. Systems and Methods for Producing Efficacious Regulatory T Cells
US20230390391A1 (en) 2020-01-22 2023-12-07 Regents Of The University Of Minnesota Bi-specific chimeric antigen receptor t cells targeting cd83 and interleukin 6 receptor
WO2023122643A1 (en) 2021-12-22 2023-06-29 Regents Of The University Of Minnesota Cd83 and allo- and autoimmune conditions
JP2024102735A (ja) 2023-01-19 2024-07-31 セイコーエプソン株式会社 頭部装着型表示装置及び光学ユニット

Similar Documents

Publication Publication Date Title
JP2021513857A5 (enExample)
JP2021087455A5 (enExample)
JP2021177771A5 (enExample)
JP2021094037A5 (enExample)
JP2025028239A5 (enExample)
JP2020114264A5 (enExample)
JP2019527557A5 (enExample)
JP2020517295A5 (enExample)
JP2025065142A5 (enExample)
HRP20241057T1 (hr) Kimerni antigenski receptori na osnovu jedno-domenskih antitijela i načini njihove uporabe
JP2020530289A5 (enExample)
JP2017524367A5 (enExample)
JP2024023228A5 (enExample)
IL277398B2 (en) Pd-l1 binding affimers, and uses related thereto
IL317912A (en) A combined chimeric antigen receptor targeting CD19 and CD20 and its applications
JP2022548778A5 (enExample)
HRP20231542T1 (hr) Kimerni antigenski receptori koji ciljaju bcma i postupci njihove uporabe
JP2020513754A5 (enExample)
TW201920653A (zh) 調節細胞表達的生物活性之結合分子
JP2023544890A5 (enExample)
JP2022507295A5 (enExample)
JP2022542543A5 (enExample)
JP2022542559A5 (enExample)
RU2018111462A (ru) Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
JP2018526028A5 (enExample)